Leadership changes with some promotions

Effective this month, Stefan Heitmann is the new CEO of PriceHubble, Europe’s leader in performance data solutions for finance and real estate. As the Founder and Executive Chairman of PriceHubble, Dr. Stefan Heitmann brings extensive knowledge and work experience in the banking and wealth industries, exemplified by his role as Partner at McKinsey & Company in Zurich until 2012, and founder and CEO of Switzerland’s leading tech-based mortgage broker MoneyPark until 2021. Having played a pivotal role in steering PriceHubble to success since its inception in 2016, Stefan Heitmann will now assume the position of Chief Executive Officer. In this role, he will guide the overall strategic direction, vision and management of PriceHubble, its global expansion and ensure continued innovation and growth in the financial and real estate industries.

Madiha Derouazi joins AC Immune as Chief Scientific Officer
AC Immune, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, has strengthened its leadership team. Effective January 1^st, 2024, Madiha Derouazi will assume the role of Chief Scientific Officer. An accomplished immunologist, Madiha previously worked at Speransa Therapeutics as CEO since inception in 2021, leading the development of a novel platform of prophylactic vaccines. Prior, she founded AMAL Therapeutics in 2012, an immuno-oncology company developing a new generation of therapeutic cancer vaccines, and served as CEO and CSO until 2022. Dr. Derouazi led AMAL’s acquisition by Boehringer Ingelheim for EUR 425 million in 2019.

Interim Chief Financial Officer Christopher Roberts has been promoted to Chief Financial Officer, bringing vast experience in SEC reporting, initial and follow-on public offerings and financial controls. He joined AC Immune in 2019 and has served as Vice President, Finance and Interim CFO of AC Immune since 2022.

Memo Therapeutics appoints Erik van den Berg as CEO
Industry veteran Erik van den Berg is the new CEO at Memo Therapeutics, the late-stage biotech company developing best-in-class therapeutic antibodies. Its lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. Mr. van den Berg joins MTx with over 25 years of industry experience and a proven track record in leading and growing companies. During his career, Mr. van den Berg has completed over 20 transactions and partnerships, including a $600 million alliance with Pfizer, a $290 million partnership with Kyowa Kirin and $500 Million in equity and debt financings for biotechnology companies from seed through IPO. He was CEO of AM-Pharma for over 12 years and remains on its Board.  

South Pole welcomes Interim CEO
John Davis, South Pole’s Commercial Director, Asia-Pacific, has assumed the role of Interim CEO following the resignation of Chief Executive Officer (CEO) Renat Heuberger. Founded in 2006, South Pole is a  climate project developer and solutions provider with over 850 projects in more than 50 countries, resulting in over 200 million metric tonnes of CO2 emissions reduction. John has been with South Pole for eight years. He led and expanded the Sustainable Finance Team during his initial four years in London. His achievements include successfully scaling and selling South Pole’s CNI business to ISS and establishing and developing the company’s commercial teams in both New York and Singapore. Based in South Pole’s Sydney office, John runs the APAC business and is an active member of the company’s Executive Committee. In his new role, he will lead South Pole’s program change, including enhancing quality assurance standards across the company’s global projects.

Oxyle appoints new COO
Dominique Kronenberg has joined Oxyle as Chief Operating Officer, bringing years of experience scaling operations and growing teams in the Deeptech sustainable space. He joins Oxyle from Climeworks, where he served for 13 years as Chief Operating Officer and Chief of Staff. As their first employee and executive team member, he was pivotal in scaling the company’s operations globally and was crucial in making it a Unicorn. He will leverage his extensive experience to oversee Oxyle’s operations and logistics, formulate a robust growth strategy, and chart a clear roadmap for the company’s future. The Swiss startup develops solutions to empower companies and municipalities to fight PFAS contamination by permanently removing them from bodies of water.

Pharvaris welcomes Chief Technical Operations Officer
Building on its deep-seated roots in hereditary angioedema (HAE), Pharvaris is developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. With Stefan Abele, as Chief Technical Operations Officer, the company has won a new team member with more than 20 years of experience in process development, end-to-end Active Pharmaceutical Ingredients (API) supply chain, cross-functional CMC activities, GMP manufacturing, global vendor management, and people leadership. He will be responsible for all chemistry, manufacturing, and controls (CMC) activities, supply chain, and program management as Pharvaris progresses into late-stage clinical development.

(Press release/RAN)
Image by FreePik